Heska Corporation (NASDAQ:HSKA) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Sunday.

A number of other equities research analysts also recently issued reports on the company. Zacks Investment Research upgraded Heska Corporation from a “hold” rating to a “buy” rating and set a $101.00 price target for the company in a research note on Thursday, May 4th. Aegis started coverage on Heska Corporation in a research note on Thursday, June 1st. They set a “buy” rating and a $114.50 price target for the company. Finally, B. Riley restated a “neutral” rating and set a $83.00 price target on shares of Heska Corporation in a research note on Friday, April 28th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $95.50.

Heska Corporation (HSKA) traded up 0.22% during trading on Friday, reaching $100.78. 25,273 shares of the company traded hands. The company’s 50-day moving average price is $96.38 and its 200 day moving average price is $89.94. Heska Corporation has a 52 week low of $41.23 and a 52 week high of $110.25. The firm has a market capitalization of $717.15 million, a price-to-earnings ratio of 53.98 and a beta of 0.81.

Heska Corporation (NASDAQ:HSKA) last released its quarterly earnings results on Tuesday, May 2nd. The medical research company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.37. The business had revenue of $30.38 million during the quarter, compared to the consensus estimate of $33.31 million. Heska Corporation had a return on equity of 15.20% and a net margin of 10.45%. Heska Corporation’s quarterly revenue was up 11.9% on a year-over-year basis. On average, equities research analysts expect that Heska Corporation will post $1.98 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Heska Corporation (HSKA) Lowered to “Hold” at BidaskClub” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/16/heska-corporation-hska-lowered-to-hold-at-bidaskclub.html.

In other Heska Corporation news, EVP Steve Asakowicz sold 382 shares of the business’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $100.08, for a total transaction of $38,230.56. Following the completion of the sale, the executive vice president now directly owns 10,382 shares in the company, valued at approximately $1,039,030.56. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Sharon J. Larson purchased 1,000 shares of the business’s stock in a transaction on Thursday, May 4th. The shares were purchased at an average price of $90.00 per share, with a total value of $90,000.00. Following the completion of the purchase, the director now owns 3,294 shares in the company, valued at $296,460. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 30,265 shares of company stock valued at $2,983,439. Corporate insiders own 14.70% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Riverbridge Partners LLC increased its position in shares of Heska Corporation by 257.0% in the first quarter. Riverbridge Partners LLC now owns 244,031 shares of the medical research company’s stock worth $25,618,000 after buying an additional 175,674 shares during the period. Neuberger Berman Group LLC increased its position in shares of Heska Corporation by 60.8% in the first quarter. Neuberger Berman Group LLC now owns 445,245 shares of the medical research company’s stock worth $46,742,000 after buying an additional 168,293 shares during the period. Vanguard Group Inc. increased its position in shares of Heska Corporation by 47.0% in the first quarter. Vanguard Group Inc. now owns 350,609 shares of the medical research company’s stock worth $36,807,000 after buying an additional 112,115 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of Heska Corporation during the first quarter worth about $5,853,000. Finally, Principal Financial Group Inc. bought a new position in shares of Heska Corporation during the first quarter worth about $5,234,000. Institutional investors own 81.78% of the company’s stock.

About Heska Corporation

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska Corporation (NASDAQ:HSKA)

Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.